A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease
Status:
Not yet recruiting
Trial end date:
2023-11-07
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to establish the safety and tolerability of multiple
ascending doses (MAD) of foralumab enteric coated capsules administered orally, once daily
for 5 days per week over 2 weeks in participants with moderate to severely active Crohn's
Disease (CD).